Erasca, Inc.
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
ERAS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US29479A1088
- LEI:
- Country:
- United States of America
- Address:
- 3115 MERRYFIELD ROW, 92121 SAN DIEGO
- Website:
- https://www.erasca.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Erasca, Inc. is a clinical-stage precision oncology company dedicated to its mission of erasing cancer. The company's primary focus is on discovering and developing therapies that target the RAS/MAPK pathway, one of the most frequently mutated signaling cascades in human cancers. Erasca advances a modality-agnostic portfolio of therapeutic programs, building a robust pipeline designed to comprehensively shut down the pathway. This approach aims to create transformative treatments for patients with a wide range of cancers driven by these mutations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Erasca, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Erasca, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Erasca, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
